Natixis’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$125M Buy
2,068,064
+522,535
+34% +$30.5M 0.45% 25
2025
Q4
$83.4M Buy
1,545,529
+857,973
+125% +$41.3M 0.3% 45
2025
Q3
$31M Buy
687,556
+329,164
+92% +$15.4M 0.14% 129
2025
Q2
$16.6M Sell
358,392
-51,702
-13% -$2.54M 0.07% 170
2025
Q1
$25.1M Sell
410,094
-834,762
-67% -$48.7M 0.14% 119
2024
Q4
$70.4M Sell
1,244,856
-108,957
-8% -$6.09M 0.43% 35
2024
Q3
$70M Sell
1,353,813
-240,118
-15% -$11.3M 0.39% 48
2024
Q2
$66.2M Buy
+1,593,931
New +$71.3M 0.38% 48
2024
Q1
Sell
-158,441
Closed -$8.13M 1024
2023
Q4
$8.13M Buy
+158,441
New +$8.32M 0.06% 243
2023
Q3
Sell
-1,298,735
Closed -$83.1M 994
2023
Q2
$83.1M Buy
1,298,735
+854,960
+193% +$57.3M 0.67% 23
2023
Q1
$30.8M Sell
443,775
-940,060
-68% -$66.3M 0.28% 81
2022
Q4
$99.6M Sell
1,383,835
-4,601,506
-77% -$347M 0.56% 44
2022
Q3
$430M Buy
5,985,341
+307,361
+5% +$22.3M 2.01% 5
2022
Q2
$436M Buy
5,677,980
+4,885,184
+616% +$372M 1.58% 6
2022
Q1
$57.9M Sell
792,796
-21,560
-3% -$1.45M 0.2% 108
2021
Q4
$50.8M Buy
814,356
+390,789
+92% +$22.9M 0.17% 103
2021
Q3
$25.1M Sell
423,567
-473,723
-53% -$31.2M 0.09% 199
2021
Q2
$59.5M Sell
897,290
-209,038
-19% -$13.6M 0.26% 84
2021
Q1
$69.8M Sell
1,106,328
-176,290
-14% -$11M 0.23% 94
2020
Q4
$79.6M Buy
+1,282,618
New +$78.9M 0.29% 73
2020
Q3
Sell
-1,052,049
Closed -$61.9M 771
2020
Q2
$61.9M Sell
1,052,049
-440,693
-30% -$26.4M 0.48% 41
2020
Q1
$83.2M Buy
1,492,742
+687,686
+85% +$42M 0.65% 37
2019
Q4
$51.3M Buy
805,056
+625,735
+349% +$35.8M 0.32% 88
2019
Q3
$9.09M Sell
179,321
-290,217
-62% -$13.6M 0.06% 272
2019
Q2
$21.3M Buy
469,538
+223,551
+91% +$10.4M 0.16% 128
2019
Q1
$11.8M Sell
245,987
-364,237
-60% -$18.1M 0.07% 249
2018
Q4
$31.7M Buy
610,224
+98,333
+19% +$5.28M 0.26% 101
2018
Q3
$31.8M Sell
511,891
-163,969
-24% -$9.73M 0.18% 128
2018
Q2
$37.1M Sell
675,860
-16,021
-2% -$865K 0.2% 116
2018
Q1
$43.5M Buy
691,881
+74,903
+12% +$4.82M 0.27% 88
2017
Q4
$37.8M Buy
616,978
+392,997
+175% +$24.6M 0.29% 91
2017
Q3
$14.3M Sell
223,981
-39,324
-15% -$2.3M 0.13% 155
2017
Q2
$14.7M Buy
+263,305
New +$14.3M 0.17% 137
2017
Q1
Sell
-301,236
Closed -$17.6M 942
2016
Q4
$17.6M Buy
301,236
+43,655
+17% +$2.39M 0.18% 142
2016
Q3
$13.9M Buy
257,581
+146,252
+131% +$9.39M 0.16% 119
2016
Q2
$8.19M Sell
111,329
-150,375
-57% -$10.6M 0.15% 133
2016
Q1
$16.7M Buy
+261,704
New +$16.5M 0.28% 68
2015
Q4
Sell
-70,374
Closed -$4.17M 315
2015
Q3
$4.17M Buy
+70,374
New +$4.46M 0.09% 90
2014
Q4
Sell
-531,417
Closed -$27.2M 388
2014
Q3
$27.2M Sell
531,417
-595,273
-53% -$29.7M 0.42% 42
2014
Q2
$54.7M Buy
1,126,690
+131,145
+13% +$6.46M 0.66% 36
2014
Q1
$51.7M Sell
995,545
-171,952
-15% -$9.15M 0.67% 36
2013
Q4
$62.1M Sell
1,167,497
-627,427
-35% -$32M 0.53% 39
2013
Q3
$83.1M Sell
1,794,924
-502,010
-22% -$22M 0.89% 19
2013
Q2
$103M Buy
+2,296,934
New +$99.7M 1.47% 10

Other funds holding BMY

Natixis's BMY Position: Q1 2026 in Review

Natixis increased its Bristol-Myers Squibb (BMY) stake by 34% in Q1 2026, buying an estimated $30.5M and bringing the position to 2,068,064 shares worth $125M. The position accounts for 0.45% of the portfolio, ranked #25.

Natixis first reported a position in BMY in Q2 2013 and has held it in 44 quarters since. The position peaked at $436M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Natixis held 2,068,064 shares of Bristol-Myers Squibb worth $125M as of Q1 2026.
  • Natixis bought 522,535 Bristol-Myers Squibb shares in Q1 2026, an estimated $30.5M.
  • Bristol-Myers Squibb made up 0.45% of Natixis's portfolio in Q1 2026, its #25 holding.
  • Natixis first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 44 quarters since.
  • Natixis's Bristol-Myers Squibb position peaked at $436M in Q2 2022.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.